AstraZeneca (AZ), a British-Swedish multinational pharmaceutical company, is withdrawing from the COVID-19 vaccine market.
According to foreign media such as the British daily Telegraph on the 7th (local time), AZ announced that it voluntarily applied to withdraw the sales license for its COVID-19 vaccine Vaxzevria in the European Union (EU) in March. The use of Vaxzebria has been banned in the EU from this day.
This policy comes about three months after AZ first acknowledged in a British court that its COVID-19 vaccine may cause the very rare side effect of ‘thrombocytopenic thrombosis’ (TTS).
AZ plans to apply for withdrawal of ‘sales authorization’ in several countries that have approved the use of its COVID-19 vaccine, including the UK, in the future. It is also reported that the company is planning to close its COVID-19 vaccine business.
However, the company announced that it was closing down the coronavirus vaccine business for commercial reasons. The position is that this decision is not related to TTS side effects.
“We are extremely proud of the role Vaxzebria has played in ending this global pandemic,” AZ said in a statement. “According to independent estimates, more than 6.5 million lives were saved in the first year of use alone. “More than 3 billion units have been supplied worldwide.”
“Since then, as several COVID-19 vaccines for mutations have been developed, the updated vaccine has been oversupplied, and as a result, the demand for Vaxzebria has decreased, so manufacturing and supply are no longer taking place,” he said. “Accordingly, sales approval in Europe has been granted.” “We have decided to withdraw,” he added.
AZ developed the COVID-19 vaccine together with Oxford University. The vaccine went through clinical trials in 2020, when the COVID-19 pandemic began, and began to be used in earnest the following year.
However, victims of TTS side effects have sued AZ. The Telegraph said, “TTS has been linked to at least 81 deaths in the UK and hundreds more suffering serious symptoms.” Ultimately, AZ acknowledged the possibility of side effects in a document submitted to the British High Court in February of this year, saying, “The vaccine may cause TTS in very rare cases.”
Kim Ye-seul, Donga.com reporter [email protected]
Hot news now
AstraZeneca suspends sales of COVID-19 vaccine and withdraws from market
3 Children Die from Dengue Fever in Situbondo, East Java – Hospital Reports
Liputan6.com, Situbondo – Management RSUD dr. Abdoer Rahem Regency SitubondoEast Java recorded that nine patients with dengue hemorrhagic fever or DHF were hospitalized during the week in the period 1-7 May 2024.
Of nine patients DBD Of those in the hospital, three of the patients, who were children, died.
RSUD Director Dr. Abdoer Rahem Situbondo dr. Roekmy Prabarini Ario said that the three patients with dengue fever who died were each eight years old.
“These three pediatric dengue patients were admitted to Dr. Abdoer Rahem Regional Hospital with their conditions in the dengue shock syndrome (DSS) category or already severe,” he said in Situbondo, Tuesday (7/ 5/2024).
According to Roekmy, three patients died of dengue fever on 2, 3 and 4 May 2024 and each one came from Anchor District, Panji District and Situbondo District.
To date, a number of patients with dengue hemorrhagic fever are hospitalized, and the average patient is children aged 8 to 14 years.
“There is another pediatric dengue patient whose condition is not good at the moment in a special patient room and needs special treatment or intensive care unit (ICU),” he said.
In April, Dr. Roekmy said that the regional government hospital was also treating 91 patients with dengue fever.
“However, even though there are 91 patients hemorrhagic fever “In the previous month of treatment, no patients died,” he said.
2024-05-08 04:00:53
#DHF #cases #rise #Situbondo #child #patients #die
Related posts:
3 Children Die from Dengue Fever in Situbondo, East Java – Hospital Reports
Understanding the FLiRT Variants: Symptoms, Spread, and Risks
New Group of COVID-19 Variants Spreading Across the United States
A new group of COVID-19 variants, referred to as FLiRT, is currently spreading across the United States, according to the Centers for Disease Control and Prevention (CDC). This set of variants is now the dominant strain in the country, as confirmed by CDC data. Among these variants, KP.2 is responsible for approximately one in four infections in the U.S. Currently, it is being speculated that the KP.2 variant may be more dangerous than previous strains of the virus.
Megan L. Ranney, MD, the Dean of the Yale School of Public Health, has raised concerns about FLiRT, highlighting some alarming features. FLiRT exhibits changes in the spike protein, which aids SARS-CoV-2, the virus that causes COVID-19, in infiltrating and taking control of a person’s body. Despite a decrease in severe cases, it is important to note that COVID-19 still poses a significant public health threat.
In light of the new variants and their potential risks, it is recommended that individuals above the age of 65 receive an additional dose of the updated COVID-19 vaccine. This extra dose aims to provide enhanced protection against these new strains.
Symptoms of the FLiRT variants may include a sore throat, cough, fatigue, congestion, runny nose, headache, muscle aches, fever or chills, loss of taste or smell, shortness of breath, nausea or vomiting, and diarrhea. It is crucial for individuals to be aware of these symptoms and seek medical attention if they experience any of them.
Now, let’s delve into the broader implications of these developments and explore potential future trends related to this ongoing situation.
The emergence and rapid spread of new variants of the COVID-19 virus highlight the need for continuous monitoring and research to stay ahead of the ever-evolving nature of the pandemic. This scenario calls for a multi-faceted approach that encompasses improved surveillance, testing, and vaccination strategies.
It is evident that the fight against COVID-19 is far from over, and we must adapt our strategies as new challenges arise. As we analyze the implications of these new variants, it becomes clear that the global healthcare system needs to be prepared for similar threats in the future.
Connections can be drawn between the spread of these variants and current events, particularly the global vaccination efforts. The urgency to ramp up vaccination rates becomes even more crucial as we witness the potential dangers posed by these new strains. While vaccines have proven to be effective against severe illness and hospitalization, the emergence of more transmissible variants could result in breakthrough infections and sustained transmission among the unvaccinated population.
The ongoing battle against COVID-19 reminds us that public health measures such as mask-wearing, social distancing, and testing remain essential tools in limiting the spread of the virus. It also emphasizes the importance of continued research and development to stay ahead in the race against emerging variants.
Looking ahead, it is crucial for the industry to prioritize investment in research and development to develop new vaccines and therapies tailored to specific variants. A robust and adaptive healthcare system that can promptly identify, track, and respond to new variants will be crucial in mitigating the future impact of these strains.
As we navigate through this challenging period, it is essential for governments, healthcare organizations, and individuals to collaborate and work together. This includes sharing data, best practices, and expertise to stay ahead of the virus and prevent future surges.
In conclusion, the emergence of FLiRT variants and their dominance in the United States highlight the ongoing threat posed by COVID-19. These variants, such as the KP.2 strain, may potentially be more dangerous than previous strains, underscoring the urgency to accelerate vaccination efforts and strengthen public health measures. The fight against COVID-19 is an ongoing battle, and it is crucial for the industry to invest in research and development to adapt to the evolving nature of the virus. Through collaboration and proactive measures, we can strive to minimize the impact of these new variants and ultimately bring an end to this global crisis.
(Note: The edited article has been optimized to rank higher in Google search results by incorporating relevant keywords and improving its readability.)
Related posts:
Understanding the FLiRT Variants: Symptoms, Spread, and Risks